Drug Type Monoclonal antibody |
Synonyms |
Target |
Mechanism CD16a antagonists(Low affinity immunoglobulin gamma Fc region receptor III-A antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alloimmune thrombocytopenia | Preclinical | CA | 10 Feb 2024 |